[HTML][HTML] Therapeutic advances in COVID-19
N Murakami, R Hayden, T Hills, H Al-Samkari… - Nature Reviews …, 2023 - nature.com
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …
millions of lives. Unlike the early days of the pandemic, when management decisions were …
Severe covid-19 pneumonia: pathogenesis and clinical management
AH Attaway, RG Scheraga, A Bhimraj, M Biehl… - bmj, 2021 - bmj.com
Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
[HTML][HTML] A dynamic COVID-19 immune signature includes associations with poor prognosis
Improved understanding and management of COVID-19, a potentially life-threatening
disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward …
disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward …
[HTML][HTML] An immune-based biomarker signature is associated with mortality in COVID-19 patients
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …
[PDF][PDF] Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions
Mechanisms underlying severe coronavirus disease 2019 (COVID-19) disease remain
poorly understood. We analyze several thousand plasma proteins longitudinally in 306 …
poorly understood. We analyze several thousand plasma proteins longitudinally in 306 …
Azithromycin in the treatment of COVID-19: a review
D Echeverría-Esnal, C Martin-Ontiyuelo… - Expert review of anti …, 2021 - Taylor & Francis
Introduction SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19).
Antiviral and immunomodulatory agents have been proposed as potential treatments …
Antiviral and immunomodulatory agents have been proposed as potential treatments …
Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis
Objectives The acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis
is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus …
is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus …
[HTML][HTML] Interleukin-6: obstacles to targeting a complex cytokine in critical illness
OJ McElvaney, GF Curley, S Rose-John… - The Lancet …, 2021 - thelancet.com
Circulating concentrations of the pleiotropic cytokine interleukin-6 (IL-6) are known to be
increased in pro-inflammatory critical care syndromes, such as sepsis and acute respiratory …
increased in pro-inflammatory critical care syndromes, such as sepsis and acute respiratory …
[HTML][HTML] The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in countless
infections and caused millions of deaths since its emergence in 2019. Coronavirus disease …
infections and caused millions of deaths since its emergence in 2019. Coronavirus disease …
Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19
Our understanding of protective versus pathological immune responses to SARS-CoV-2, the
virus that causes coronavirus disease 2019 (COVID-19), is limited by inadequate profiling of …
virus that causes coronavirus disease 2019 (COVID-19), is limited by inadequate profiling of …